argenx SE
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
21 jun 2023 - 00:20
Statutory name
argenx SE
Title
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
Date last update: 15 October 2026